It has been a bumper year for Denali Therapeutics, Inc. DNLI. Shares of the company have surged 25.4% year to date compared with the industry’s gain of 2.7%. The stock has outperformed the sector

Cytokinetics, Incorporated CYTK has entered a pivotal phase following the FDA approval of its first commercial product, Myqorzo (aficamten), for the treatment of symptomatic obstructive hypertrophic

FTI Consulting FCN stock is a compelling candidate, supported by its diversified business model, strong global presence, and rising demand for its specialized consulting services. While the broader

The semiconductor industry has received some good news this week following the announcement that Broadcom AVGO and Meta Platforms META have deepened their multi-year partnership through 2029, to

For the past few years, analysts have been defining the UK economy by a stubborn sense of "permacrisis." Following the post-pandemic inflationary spike and the energy shocks of 2022, the national

GE Vernova Inc. GEV is expected to report first-quarter 2026 results on April 22, before market open. The Zacks Consensus Estimate for earnings is pegged at $1.79 per share, indicating

Draganfly’s DPRO is building momentum through deeper engagement with key U.S. defense entities, including the U.S. Air Force and the U.S. Army. These partnerships extend beyond signaling value

Boston Scientific BSX is slated to report first-quarter 2026 results on April 22, before market open.

In the last reported quarter, the renowned medical device manufacturer posted earnings per share

GE Aerospace GE is scheduled to release first-quarter 2026 results on April 21, before market open. The Zacks Consensus Estimate for quarterly earnings is currently pegged at $1.63 per share on